Encompass Health Corporation (EHC) Stock

Understand Encompass Health Corporation: how it makes money

Encompass Health runs specialized inpatient rehabilitation centers and home health agencies treating patients recovering from stroke, cardiac, and neurological conditions, billing Medicare and insurers per discharge. Revenue per patient is driven by acuity, so growth hinges on both Medicare pricing and the volume of complex post-hospital patients.

Revenue equals discharges times net revenue per stay, where patient acuity sets both the length of stay and the reimbursement rate; the specialty focus on complex neuro and cardiac cases is what pulls in the high-acuity patients that general hospitals cannot keep for rehabilitation.

Business quality (Mixed): Solid but policy-exposed: 16% operating margin and 10% revenue growth show a functioning model, yet Medicare rate and MA plan policy can reset the top line without warning, keeping the business in 'mixed' territory.

Valuation: At 19× earnings, EHC trades 24% below the Healthcare Services average (25×).

Bull case

• VA contracts accelerating: VA growth reached 33%, with management estimating treatment of nearly 10,000 veterans by year-end, adding a stable, government-backed payer that diversifies revenue away from commercial contract negotiations.
• Medicare rate lift ahead: Management expects higher Medicare rates to increase net revenue per discharge by approximately 2.3%, a structural pricing step-up that compounds on the 10% revenue growth already delivered this quarter.
• Trades at a 24% discount: At 19.2x earnings versus a 25x Healthcare Services industry average, the stock prices in a persistence risk that the current 16% operating margin and steady revenue trajectory do not evidence.

Bear case

• Advantage denials squeeze volume: Medicare Advantage denials remain materially worse than fee-for-service Medicare, and as the payer mix tilts toward MA plans, each denied case is a discharge that never converts into billable revenue.
• Tax benefit halved: The 2026 provider-tax EBITDA benefit was reduced from approximately $21 million to $10 million, meaning the reported earnings this year overstate the underlying run-rate by roughly $11 million and future quarters lose that cushion.
• Labor leverage running out: Management cited diminishing returns on premium-labor savings, signaling that the cost-side levers supporting margin expansion have limited remaining headroom and future EBITDA gains must come almost entirely from the top line.

Related Companies (Healthcare Services; 8 comparable companies)

• Select Medical Holdings Corporation (SEM)
• Pediatrix Medical Group, Inc. (MD)
• Agilon Health, Inc. (AGL)
• Option Care Health, Inc. (OPCH)
• Ardent Health Partners, LLC (ARDT)
• PACS Group, Inc. (PACS)
• The Ensign Group, Inc. (ENSG)
• Acadia Healthcare Company, Inc. (ACHC)